Fig. 1S
Effects of pathway inhibitor combination treatment on PDGF-BB-induced proliferation and migration of HASMCs. (A) Serum-starved HASMCs were pretreated with 10 µM LY294009, SB203580, or SP600125 as indicated, or a combination of each of the three inhibitors (Combi) for 1 h, prior to stimulation with 10 ng/mL PDGF-BB for 48 h. Data are represented as mean ±SEM values of at least three independent experiments. (B) Serum-starved HASMCs were pretreated with 10 µM LY294009, SB203580, SP600125, or combination of 10 µM of each of the three inhibitors (Combi) for 1 h, prior to stimulation with 10 ng/mL PDGF-BB. Thereafter, the widths of the injury lines were measured at 0, 12, 18, and 24 h. Results are expressed as the average widths of the injury lines relative to untreated controls at 0 h, as determined from at least three independent experiments. Data are represented as mean ±SEM values. Means with letters (a-d) within the graph are significantly different from each other at p < 0.05.
